email@email.com
Request a Call
Contact Online
Subscribe |
| Log In
The most widely read newsletter on China's life science industry.
Toggle navigation
Home
Subscribe
Top Stories
Hot Topics
Search
Conferences
Consulting
About Us
Contact Us
You are here:
All Products
Articles
Instant access to selected
ChinaBio® Today
subscriber-only articles.
Browse
All Products
Articles
Viewing
136 - 150
of 3612 products
View All
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
Next
Gracell, a CAR-T Company, to be Acquired by AstraZeneca for $1.2 Billion
$5.00
Available
LianBio Sells China Rights for Radioenhanced Drug to Janssen for $30 Million
$5.00
Available
Huadong to Promote Impact’s PARP Inhibitor in China in $40 Million Agreement
$5.00
Available
Ablaze Medicine Partners with Oncoshot for AI-based Optimization of Clinical Trials
$5.00
Available
CStone Sells China Rights for IDH1 Inhibitor to Servier Pharma for $50 Million
$5.00
Available
CellOrigin Starts China Trial of Macrophage-based CAR Therapy
$5.00
Available
GSK Acquires ex-China Rights to Second ADC from Hansoh in $1.7 Billion Deal
$5.00
Available
InxMed Licenses Rights to Escugen’s Linker-Payload Platform for ADC Candidates
$5.00
Available
RNAimmune Approved to Start US Trials of mRNA Vaccine for RSV
$5.00
Available
Nona Out-licenses MSLN-targeting ADC to Pfizer in $1 Billion Agreement
$5.00
Available
GeneQuantum and BioMap Form AI Collaboration to Discover Novel ADC Candidates
$5.00
Available
Fosun Pharma Receives Support for Phase III Trial of Triple Artemisinin Therapy for Malaria
$5.00
Available
Alebund Reports Positive Phase II Data for Novel Therapy Aimed at Dialysis Side Effects
$5.00
Available
Evive and Nona Partner Up to Develop Antibody Drugs
$5.00
Available
SystImmune Out-Licenses Rights for ADC to BMS in $8.4 Billion Agreement
$5.00
Available